Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350168 · ClinicalTrials.gov registry record · Phase 3
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension
A Phase 3 study of Hypertension, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 647
- Enrollment target
- 1
- Study location
NCT00350168 is a Phase 3 study of Hypertension that has completed, run by Novartis. The registered enrollment target is 647 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00350168, a Phase 3 study of Hypertension, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 647 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Conditions Studied
Interventions
- DRUG valsartan + amlodipine
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals Corp - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 647 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350168
The ClinicalTrials.gov registry entry for NCT00350168 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 647 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (82% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which valsartan + amlodipine is the first listed.
NCT00350168 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00350168 about?
NCT00350168 is a clinical study titled "Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension". The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
What is the current status of trial NCT00350168?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 647 participants. The study started on 2006-06. Estimated completion is 2007-04.
What conditions does trial NCT00350168 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00350168?
The interventions under investigation include: valsartan + amlodipine (DRUG).
Who is sponsoring clinical trial NCT00350168?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350168 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.